This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Paul McBarron - Chief Financial Officer, Chief Operating Officer, Executive Vice President of Finance, Principal Accounting Officer, Secretary and Executive Director
Judy H. Chiao - Chief Medical Officer and Vice President of Clinical Development & Regulatory Affairs
Ladies and gentlemen, thank you for standing by, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2012 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Corey Sohmer. Sir, you may begin your conference.
Thank you. Good afternoon and welcome to our quarterly conference call. During today's call, members of our senior management team will review Cyclacel's financial performance and business highlights for the second quarter ended June 30, 2012.
Before turning the call over to senior management, I would like to remind everyone that during this conference call, any forward-looking statements made by management are intended to fall within the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities and Exchange Act of 1934 as amended.
As set forth in our press release, forward-looking statements involve risks and uncertainties that may affect the company's business and prospects, including those discussed in our filings with the SEC, which include among others, our Form 10-K. These filings are available from our -- from the SEC or our website. All of our projections and other forward-looking statements represent our judgment as of today and Cyclacel does not take any responsibility to update such information.